Ranbaxy extends losses in Q3 but merger with Sun on track
This article was originally published in Scrip
Ahead of its proposed combination with Sun Pharma, Ranbaxy Laboratories reported disappointing numbers for the third quarter ended December 2014, with net losses widening to INR10.29bn ($168m) dented by higher finance costs and foreign exchange losses.
You may also be interested in...
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.
A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.